Guttate psoriasis secondary to COVID-19

Gananandan, Kohilan; Sacks, Benjamin N.; Ewing, Iain

doi:10.1136/bcr-2020-237367

Cited by 43 publications

(39 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…So far (August 2020), two cases of plaque psoriasis and one case of guttate psoriasis have been reported secondary to COVID-19. [4][5][6] Ozaras et al, who reported one case of plaque psoriasis, found that after COVID-19 treatment, the patient's psoriatic lesions also regressed without any specific treatment 4 ; in other words, COVID-19 was responsible for these lesions. Here, we reported the first case of pustular psoriasis, exacerbated by COVID-19.…”

Section: Covid-19 and The Positive Results Of Polymerase Chain Reactimentioning

confidence: 99%

Pustular psoriasis exacerbated by COVID ‐19 in a patient with the history of psoriasis

Shakoei

Ghanadan

Hamzelou

2020

Dermatologic Therapy

View full text Add to dashboard Cite

The recent coronavirus disease (COVID-19), which was first reported in China, has spread around the world, causing major public health concerns. 1 Several treatments have been proposed for the treatment of COVID-19, including hydroxychloroquine, monoclonal antibodies, corticosteroids, favipiravir, lopinavir/ritonavir, anticoagulants, and azithromycin. 2 Here, we present a case of pustular psoriasis, exacerbated by COVID-19 in a patient with a history of hydroxychloroquine use. Patient consent for publication is achieved. The patient was a 47-year-old woman, presenting with pustular lesions over the past 3 weeks. The COVID-19 symptoms, including sore throat, myalgia, fever, and dry cough (for 8 days), had developed over the past 6 weeks. The chest computed tomography (CT) scan showed bilateral peripheral ground-glass opacities and infiltrations. Oxygen saturation was in the normal range. She was tested for

show abstract

Section: Covid-19 and The Positive Results Of Polymerase Chain Reactimentioning

confidence: 99%

Pustular psoriasis exacerbated by COVID ‐19 in a patient with the history of psoriasis

Shakoei

Ghanadan

Hamzelou

2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Flares of psoriasis or newly-developed psoriatic arthritis concurrent with or following COVID-19 infection had been reported. These conditions had resolved either spontaneously or after NSAID and topical corticosteroids treatment (139)(140)(141). In summary, cutaneous vasculitis were potentially associated with COVID-19 infection, mainly in the Western population.…”

Section: Skin Manifestationsmentioning

confidence: 97%

Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review

2021

View full text Add to dashboard Cite

Background: Numerous cases of the coronavirus disease 2019 (COVID-19) with autoimmune and rheumatic manifestations have been reported. Despite the available reviews that summarized its autoimmune/rheumatic manifestations, a systematic approach is still lacking. Therefore, we conducted a comprehensive systematic review in order to give an overview upon these rare but clinically significant manifestations.Methods: We performed a literature search of PubMed and EMBASE as of October 9, 2020. All articles relevant to either systemic or organ-specific autoimmune and rheumatic manifestations potentially associated with COVID-19 were collected. The reviewed literature were limited to adults ≥18 years.Results: Although most of the existing evidence was based on case reports or case series without a long-term follow-up, a variety of autoimmune/rheumatic manifestations were associated with COVID-19. The manifestations that have a consistent association with COVID-19 include autoimmune cytopenia, cutaneous vasculitis, encephalitis, and Guillain-Barre syndrome. Such association is conflicting as regards to antiphospholipid syndrome, hemophagocytic lymphohistiocytosis, and myasthenia gravis.Conclusion: Our systematic review indicated the potential of the COVID-19 virus to trigger a myriad of autoimmune and rheumatic manifestations, which should be considered amid global efforts to combat COVID-19.

show abstract

“… 33 There is also a case report of a 38-year-old-man with a history of chronic plaque psoriasis who suffered from guttate psoriasis secondary to COVID-19, which appeared on the sixth day after the onset of fever. 34 Subsequently, a 45-year-old male was reported with recurrence of severe psoriatic erythroderma and a positive test for SARS‐CoV-2, but also Staphylococcus aureus isolated from blood culture samples. Given this patient’s discontinuation of cyclosporine A 3 weeks prior, it is safe to assume that SARS‐CoV-2 was not the only contributing factor to psoriasis exacerbation.…”

Section: Review Of the Literature And Discussionmentioning

confidence: 99%

Acrodermatitis Continua of Hallopeau Evolving into Generalized Pustular Psoriasis Following COVID‐19: A Case Report of a Successful Treatment with Infliximab in Combination with Acitretin

Samotij¹,

Gawron²,

Szczęch³

et al. 2021

BTT

View full text Add to dashboard Cite

Guttate psoriasis secondary to COVID-19

Cited by 43 publications

References 5 publications

Pustular psoriasis exacerbated by COVID ‐19 in a patient with the history of psoriasis

Pustular psoriasis exacerbated by COVID ‐19 in a patient with the history of psoriasis

Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review

Acrodermatitis Continua of Hallopeau Evolving into Generalized Pustular Psoriasis Following COVID‐19: A Case Report of a Successful Treatment with Infliximab in Combination with Acitretin

Contact Info

Product

Resources

About